Dr Baldo Scassellati Sforzolini

Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis

Atopic dermatitis is the most common type of eczema. Moderate to severe atopic dermatitis is a chronic and incurable condition,…

Read More »